Kyntra Bio (KYNB) Stock Price

Kyntra Bio Price

NASDAQ·CLOSED
7.52USD+0.20 (+2.70 %)
Market closed

Revenue at Kyntra Bio has contracted by 16.4% per year over the past 13 years to 6.44 M USD. Kyntra Bio's net margin stands at 2,848.6%, up from -123.3% several years earlier. Analysts set a median price target of 43.86 USD, implying 483.2% above the current price. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 16% above its 52-week low.

Kyntra Bio stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Kyntra Bio over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Kyntra Bio stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Kyntra Bio's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Kyntra Bio Stock Price History
DateKyntra Bio Price
8/21/20267.52 USD
8/20/20267.32 USD
8/19/20267.01 USD
8/18/20267.05 USD
8/17/20266.81 USD
8/14/20267.05 USD
8/13/20267.04 USD
8/12/20267.23 USD
8/10/20266.97 USD
8/7/20267.27 USD
8/6/20266.98 USD
8/5/20266.98 USD
8/4/20267.00 USD
8/3/20266.76 USD
7/31/20266.73 USD
7/30/20266.79 USD
7/29/20266.78 USD
7/28/20266.97 USD
7/27/20267.07 USD
7/23/20267.07 USD
7/22/20267.22 USD
7/21/20267.30 USD
7/20/20267.04 USD
7/17/20267.23 USD
7/16/20267.39 USD
7/15/20267.21 USD
7/14/20267.32 USD
7/13/20267.39 USD
7/10/20267.61 USD
7/9/20267.32 USD
7/8/20267.45 USD
7/7/20267.54 USD
7/6/20267.45 USD
7/2/20267.63 USD
7/1/20267.55 USD
6/30/20267.55 USD
6/29/20267.31 USD
6/26/20267.24 USD
6/25/20266.94 USD
6/24/20266.94 USD
6/23/20266.97 USD
6/22/20266.74 USD
6/18/20266.70 USD
6/17/20266.91 USD
6/16/20266.91 USD
6/15/20266.87 USD
6/12/20267.13 USD
6/11/20266.76 USD
6/10/20266.69 USD
6/9/20266.69 USD
6/8/20266.63 USD
6/5/20266.71 USD
6/4/20266.81 USD
6/3/20266.81 USD
6/2/20266.84 USD
6/1/20266.90 USD
5/29/20266.90 USD
5/28/20267.02 USD
5/27/20267.01 USD
5/26/20266.85 USD
5/22/20266.99 USD
5/21/20266.94 USD
5/20/20266.95 USD
5/19/20266.80 USD
5/18/20266.83 USD
5/15/20266.82 USD
5/14/20267.01 USD
5/13/20267.00 USD
5/12/20267.22 USD
5/11/20266.80 USD
5/8/20266.95 USD
5/7/20267.10 USD
5/6/20267.12 USD
5/5/20267.10 USD
5/4/20267.20 USD
5/1/20267.09 USD
4/30/20267.27 USD
4/29/20267.05 USD
4/28/20267.05 USD
4/27/20267.03 USD
4/24/20267.14 USD
4/23/20267.01 USD
4/22/20267.19 USD
4/21/20267.06 USD
4/20/20267.34 USD
4/17/20267.32 USD
4/16/20267.19 USD
4/15/20267.12 USD
4/14/20267.37 USD
4/13/20267.08 USD
4/10/20267.17 USD
4/9/20267.19 USD
4/8/20267.30 USD
4/7/20266.92 USD
4/6/20266.98 USD
4/2/20267.01 USD
4/1/20267.10 USD
3/31/20266.78 USD
3/30/20266.46 USD
3/27/20266.59 USD
3/26/20266.54 USD
3/25/20266.79 USD
3/24/20266.75 USD
3/23/20267.06 USD
3/20/20267.13 USD
3/19/20267.30 USD
3/18/20267.30 USD
3/17/20267.37 USD
3/16/20267.00 USD
3/13/20266.97 USD
3/12/20267.02 USD
3/11/20267.12 USD
3/10/20267.13 USD
3/9/20267.34 USD
3/6/20266.84 USD
3/5/20266.89 USD
3/4/20266.92 USD
3/3/20266.84 USD
3/2/20267.05 USD
2/27/20266.93 USD
2/26/20266.97 USD
2/25/20267.27 USD
2/24/20267.28 USD
2/23/20268.05 USD
2/20/20268.32 USD
2/19/20267.84 USD
2/18/20267.79 USD
2/17/20267.33 USD
2/13/20267.45 USD
2/12/20267.48 USD
2/11/20267.80 USD
2/10/20267.78 USD
2/9/20267.83 USD
2/6/20268.22 USD
2/5/20267.50 USD
2/4/20267.86 USD
2/3/20268.50 USD
2/2/20268.16 USD
1/30/20267.88 USD
1/29/20268.01 USD
1/28/20268.77 USD
1/27/20268.43 USD
1/26/20268.53 USD
1/23/20268.74 USD
1/22/20268.97 USD
1/21/20268.74 USD
1/20/20268.55 USD
1/16/20269.14 USD
1/15/20269.07 USD
1/14/20269.50 USD
1/13/20269.13 USD
1/12/20269.07 USD
1/9/20269.22 USD
1/8/20269.22 USD
1/7/20269.50 USD
1/6/20269.02 USD
1/5/20268.93 USD
1/2/20269.16 USD
12/31/20258.78 USD
12/30/20258.70 USD
12/29/20258.78 USD
12/26/20258.90 USD
12/24/20258.59 USD
12/23/20258.43 USD
12/22/20258.56 USD
12/19/20258.60 USD
12/18/20258.32 USD
12/17/20258.66 USD
12/16/20259.51 USD
12/15/202510.04 USD
12/12/20258.38 USD
12/11/20258.70 USD
12/10/20258.82 USD
12/9/20258.51 USD
12/8/20258.36 USD
12/5/20258.42 USD
12/4/20258.25 USD
12/3/20258.12 USD
12/2/20258.08 USD
12/1/20258.53 USD
11/28/20258.80 USD
11/26/20258.85 USD
11/25/20258.56 USD
11/24/20258.58 USD
11/21/20258.42 USD
11/20/20258.30 USD
11/19/20258.55 USD
11/18/20258.60 USD
11/17/20258.70 USD
11/14/20258.69 USD
11/13/20259.07 USD
11/12/20259.13 USD
11/11/20259.94 USD
11/10/202511.00 USD
11/7/202511.03 USD
11/6/202511.00 USD
11/5/202511.00 USD
11/4/202511.00 USD
11/3/202511.01 USD
10/31/202511.12 USD
10/30/202511.04 USD
10/29/202510.91 USD
10/28/202510.81 USD
10/27/202511.12 USD
10/24/202510.83 USD
10/23/202510.71 USD
10/22/202511.18 USD
10/21/202511.15 USD
10/20/202511.14 USD
10/17/202510.38 USD
10/16/202510.77 USD
10/15/202511.04 USD
10/14/202511.07 USD
10/13/202510.97 USD
10/10/202510.55 USD
10/9/202510.96 USD
10/8/202511.40 USD
10/7/202511.07 USD
10/6/202511.31 USD
10/3/202511.73 USD
10/2/202511.93 USD
10/1/202512.02 USD
9/30/202512.25 USD
9/29/202512.31 USD
9/26/202512.31 USD
9/25/202512.24 USD
9/24/202512.38 USD
9/23/202511.97 USD
9/22/202512.23 USD
9/19/202511.31 USD
9/18/202511.38 USD
9/17/202511.14 USD
9/16/202511.51 USD
9/15/202511.84 USD
9/12/202512.03 USD
9/11/202512.43 USD
9/10/202511.51 USD
9/9/202511.48 USD
9/8/202511.16 USD
9/5/202512.10 USD
9/4/202511.31 USD
9/3/202511.96 USD
9/2/202512.18 USD
8/29/202511.83 USD
8/28/202511.13 USD
8/27/202510.48 USD
8/26/202510.35 USD
Access this data via the Eulerpool API
Get Free API Key

Kyntra Bio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
46.80 M USD
-322.72 M USD
-284.23 M USD
Jan 1, 2024
29.62 M USD
-145.12 M USD
-47.58 M USD
Jan 1, 2025
6.44 M USD
-52.48 M USD
183.45 M USD
Jan 1, 2026 (e)
9.95 M USD
-9.95 M USD
-55.68 M USD
Jan 1, 2027 (e)
8.81 M USD
-8.81 M USD
-46.32 M USD
Jan 1, 2028 (e)
8.59 M USD
-8.59 M USD
-50.41 M USD
Jan 1, 2029 (e)
11.75 M USD
-11.75 M USD
-90.29 M USD
Jan 1, 2030 (e)
39.59 M USD
-39.59 M USD
-107.78 M USD

Kyntra Bio Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 26, 2026, 7:42 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
180.00179.00125.00212.00256.00176.00235.00140.0046.0029.006.009.008.008.0011.0039.00
31.39-0.56-30.1769.6020.75-31.2533.52-40.43-67.14-36.96-79.3150.00-11.11–37.50254.55
-18.33-3.91-56.00-10.3899.6194.89-90.6485.7191.3048.2883.3383.3383.3383.3383.3383.33
-33.00-7.00-70.00-22.00255.00167.00-213.00120.0042.0014.005.007.506.676.679.1732.50
-77.00-53.00-122.00-86.00-89.00-191.00-348.00-301.00-322.00-145.00-52.00-9.00-8.00-8.00-11.00-39.00
-42.78-29.61-97.60-40.57-34.77-108.52-148.09-215.00-700.00-500.00-866.67-100.00-100.00-100.00-100.00-100.00
-85.00-61.00-126.00-86.00-76.00-189.00-290.00-293.00-284.00-47.00183.00-55.00-46.00-50.00-90.00-107.00
44.07-28.24106.56-31.75-11.63148.6853.441.03-3.07-83.45-489.36-130.05-16.368.7080.0018.89
62.1864.0482.1591.2687.3591.1792.7794.0398.504.034.044.044.044.044.044.04
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Kyntra Bio generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Kyntra Bio retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Kyntra Bio's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Kyntra Bio has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Kyntra Bio's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Kyntra Bio stock margins

The Kyntra Bio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kyntra Bio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kyntra Bio.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
-90.89 %
-148.12 %
-123.25 %
Jan 1, 2022
85.59 %
-213.90 %
-208.66 %
Jan 1, 2023
91.53 %
-689.53 %
-607.29 %
Jan 1, 2024
47.47 %
-489.92 %
-160.63 %
Jan 1, 2025
91.37 %
-814.88 %
2,848.63 %
Jan 1, 2026 (e)
91.37 %
-100.00 %
-559.87 %
Jan 1, 2027 (e)
91.37 %
-100.00 %
-526.01 %
Jan 1, 2028 (e)
91.37 %
-100.00 %
-586.99 %

Kyntra Bio Stock Revenue, EBIT, Earnings per Share

The Kyntra Bio earnings per share therefore indicates how much revenue Kyntra Bio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
2.54 USD
-3.76 USD
-3.13 USD
Jan 1, 2022
1.50 USD
-3.20 USD
-3.12 USD
Jan 1, 2023
0.48 USD
-3.28 USD
-2.89 USD
Jan 1, 2024
7.34 USD
-35.98 USD
-11.80 USD
Jan 1, 2025
1.59 USD
-12.98 USD
45.38 USD
Jan 1, 2026 (e)
2.46 USD
-2.46 USD
-13.75 USD
Jan 1, 2027 (e)
2.17 USD
-2.18 USD
-11.44 USD
Jan 1, 2028 (e)
2.12 USD
-2.12 USD
-12.45 USD

Kyntra Bio business model & stock analysis

Kyntra Bio Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Kyntra Bio Employees
Details
Date
Kyntra Bio Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Kyntra Bio Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Kyntra Bio historical P/E ratio, EBIT multiple, and P/S ratio

Kyntra Bio annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Kyntra Bio shares outstanding

The number of shares of Kyntra Bio was 4.04 M in 2025. This indicates how many shares Kyntra Bio is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
92.77 M Stocks
Jan 1, 2022
94.03 M Stocks
Jan 1, 2023
98.50 M Stocks
Jan 1, 2024
4.03 M Stocks
Jan 1, 2025
4.04 M Stocks
Jan 1, 2026 (e)
4.04 M Stocks
Jan 1, 2027 (e)
4.04 M Stocks
Jan 1, 2028 (e)
4.04 M Stocks

Current Kyntra Bio forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
75.00 % (6)
Hold
25.00 % (2)
Sell
0.00 % (0)
12M Price Target
43.86
Last Price
7.75
Currency
USD
12M Return Potential
465.94 %
LTM Return
0 %

Kyntra Bio Analyst Rating Actions

DateFirmActionRatingReliability
9/24/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
8/7/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
8/7/2023
B of A Securities
B of A Securities
DowngradeNeutralUnderperform66
6/26/2023
Goldman Sachs
Goldman Sachs
MaintainedSell51
6/25/2023
William Blair
William Blair
DowngradeOutperformMarket Perform–
6/25/2023
Stifel
Stifel
DowngradeBuyHold56
6/25/2023
Raymond James
Raymond James
DowngradeOutperformMarket Perform62
6/25/2023
B of A Securities
B of A Securities
DowngradeBuyNeutral66
6/1/2023
Stifel
Stifel
UpgradeHoldBuy56
2/27/2023
Cowen & Co.
Cowen & Co.
MaintainedMarket Perform58

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Kyntra Bio Earnings Calls

2025

Kyntra Bio Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/13/2026-3.25USD-2.05 MUSD-2026 Q2
5/11/2026-3.42USD-1.34 MUSD-2026 Q1
3/16/2026-3.96USD-1.45 MUSD-2025 Q4

EESG©

Eulerpool ESG Scorecard© for the Kyntra Bio stock

83/100
90
Environment
99
Social
59
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Kyntra Bio shareholder structure

% Name
8.29630%
Armistice Capital LLC
Armistice Capital LLC
4.39605%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
3.43509%
Acadian Asset Management LLC
Acadian Asset Management LLC
2.21472%
PRIMECAP Management Company
PRIMECAP Management Company
2.07501%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
1.78519%
Marshall Wace LLP
Marshall Wace LLP
...

Kyntra Bio Beneficial Ownership Filings (SEC 13D/G)

Free Float
88.0%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
9.88%
Armistice Capital, LLC
Armistice Capital, LLC
SEC ↗
4.58%
PRIMECAP MANAGEMENT CO/CA/
PRIMECAP MANAGEMENT CO/CA/
SEC ↗
4.40%
The Vanguard Group
The Vanguard Group
SEC ↗

Kyntra Bio Executives and Management Board

7 members · avg. age 60 · 29 % women

TW

Mr. Thane Wettig (60)

Chief Executive Officer, Director · since 2020

2.64 M USD

Management

CC

Ms. Christine Chung (57)

Senior Vice President, China Operations

1.18 M USD
DD

Mr. David Delucia (36)

Chief Financial Officer

686,153.00 USD

Board of Directors

JS

Mr. James Schoeneck (67)

Independent Chairman of the Board · since 2010

189,360.00 USD
JE

Mr. Jeffrey Edwards (64)

Independent Director

143,735.00 USD
MH

Dr. Maykin Ho (72)

Independent Director

132,485.00 USD
MK

Dr. Michael Kauffman (61)

Director

–

Frequently asked questions about Kyntra Bio

Analysts currently set an average price target of 43.86 USD for the Kyntra Bio stock (median: 43.86 USD), implying +465.9 % versus the latest price. The consensus is based on 8 analyst ratings.

Kyntra Bio Analyst Price Targets 2026

8 analysts currently rate the Kyntra Bio stock: 6 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Kyntra Bio to generate revenue of 9.95 M USD and earnings per share of -13.77 USD.

Kyntra Bio Analyst Price Targets 2026

Converted at the current exchange rate, the Kyntra Bio share trades at 6.44 EUR (7.52 USD).

The Kyntra Bio share (KYNB) is listed on 6 stock exchanges, including: NASDAQ (FGEN), Frankfurt (1FG.F), Düsseldorf (1FG.DU), London (0IL8.L), London (0IL8.L), SIX (Zürich) (1FG.SW).

No history available for Kyntra Bio.

The expected revenue of Kyntra Bio is 9.95 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Kyntra Bio is -55.68 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Kyntra Bio is currently -0.55. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Kyntra Bio stock.

The price-to-sales ratio (P/S) of Kyntra Bio is currently 3.06. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Kyntra Bio stock.

The Eulerpool Quality Score for Kyntra Bio is 3/10.

The ISIN of Kyntra Bio is US31572Q8814. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Kyntra Bio is A12EZ0. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Kyntra Bio is KYNB. The ticker symbol is used to trade Kyntra Bio shares on the stock exchange.

Kyntra Bio paid dividends every year for the past 0 years.

Kyntra Bio is assigned to the 'Health' sector.

The dividends of Kyntra Bio are distributed in USD.

All fundamentals and in-depth analysis of Kyntra Bio

Our stock analysis for Kyntra Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kyntra Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Kyntra Bio Stock
Kyntra Bio Revenue→
Kyntra Bio Stock
Kyntra Bio Net Income→
Kyntra Bio Stock
Kyntra Bio P/E→
Kyntra Bio Stock
Kyntra Bio P/S→
Kyntra Bio Stock
Kyntra Bio EBIT→
Kyntra Bio Stock
Kyntra Bio Dividend→
Kyntra Bio Stock
Kyntra Bio Directors Dealings→
Kyntra Bio Stock
Kyntra Bio Stocks→
Kyntra Bio Stock
Kyntra Bio Market capitalization→
Kyntra Bio Stock
Kyntra Bio Debt→
Kyntra Bio Stock
Kyntra Bio Liabilities→
Kyntra Bio Stock
Kyntra Bio Equity→
Kyntra Bio Stock
Kyntra Bio AAQS→
Kyntra Bio Stock
Kyntra Bio Employees→
Kyntra Bio Stock
Kyntra Bio ROE→
Kyntra Bio Stock
Kyntra Bio ROA→
Kyntra Bio Stock
Kyntra Bio ROCE→
Kyntra Bio Stock
Kyntra Bio News→
Kyntra Bio Stock
Kyntra Bio Analyst Price Targets→

Health Stocks

Kyongbo Pharmaceutical CoKymera TherapeuticsKyorin Pharmaceutical CoKwangdong Pharmaceutical CoKyowa Kirin CoKwality PharmaceuticalsKyung Dong Pharmaceutical CoKuvatris TherapeuticsKyung Nam Pharm CoKura OncologyL&C Bio CoKun Peng InternationalAll Stocks A–Z →